Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thai Trials Of AIDS Vaccine Effectiveness Said Lowered By Full Analysis

This article was originally published in PharmAsia News

Executive Summary

Thailand trials of a vaccine against AIDS were much less effective than initially believed, based on partial data, according to a final analysis of the tests

Thailand trials of a vaccine against AIDS were much less effective than initially believed, based on partial data, according to a final analysis of the tests.

The huge three-year trial tested the RV144 vaccine's effectiveness on 16,400 participants. Initial reports suggested the vaccine had prevented the disease in 31 percent of trial participants. Although short of the level of effectiveness that would have gained the vaccine approval, the rate was considered significant. Complete analysis now shows the effectiveness of the six-shot vaccine is even lower. (Click here for more)

"AIDS Vaccine Trial Shows Only Slight Protection" - New York Times (U.S.) (10/20/09)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel